WallStSmart
MBIO

Mustang Bio Inc

NASDAQ: MBIO · HEALTHCARE · BIOTECHNOLOGY

$0.66
-2.90% today

Updated 2026-06-05

Market cap
$5.43M
P/E ratio
P/S ratio
2,205.73x
EPS (TTM)
$-0.48
Dividend yield
52W range
$1 – $4
Volume
0.1M

Mustang Bio Inc (MBIO) Financial statements

SEC filings — annual and quarterly data.

Profit margin
0.00%
Operating margin
0.00%
ROE
-31.68%
ROA
-12.90%
Debt/equity

Margin trends — annual

Gross margin Operating margin Profit margin
YearRevenueNet incomeGross marginOp. marginProfit margin
2015$0.00$-4.47M
2016$0.00$-12.65M
2017$0.00$-31.29M
2018$0.00$-30.66M
2019$0.00$-48.16M
2020$0.00$-60.02M
2021$0.00$-66.37M
2022$0.00$-77.53M
2023$0.00$-51.60M
2024$0.00$-15.75M
2025$0.00$-1.92M

Frequently asked questions

What is Mustang Bio Inc's revenue?

Mustang Bio Inc's trailing twelve-month revenue is $-50000.00. Revenue is the top line the whole model builds on, and at this scale the question shifts from how fast it grows to whether margins hold as it compounds.

How much free cash flow does MBIO generate?

MBIO produced $-5.26M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is MBIO's balance sheet healthy?

MBIO holds $17.27M in cash and equivalents against — in long-term debt, on $9.53M of shareholder equity. That debt is best read against the cash flow the business throws off each year.